Cliff Asness's IDXX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 135,154 shares of IDEXX Laboratories, Inc. (IDXX) worth $85.4 M, representing 0.05% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in IDXX, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2016, adding 86,427 shares. Largest reduction occurred in Q2 2019, reducing 130,386 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's IDEXX Laboratories (IDXX) Holding Value Over Time
Track share changes against reported price movement
Quarterly IDEXX Laboratories (IDXX) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +28,182 | Add 0.00% | 28,180 | $46.42 |
| Q2 2013 | +34,414 | Add 0.00% | 34,412 | $44.90 |
| Q3 2013 | +9,954 | Add 28.93% | 44,366 | $49.84 |
| Q4 2013 | +22,784 | Add 51.35% | 67,150 | $53.18 |
| Q1 2014 | -3,184 | Reduce 4.74% | 63,966 | $60.70 |
| Q2 2014 | -7,800 | Reduce 12.19% | 56,166 | $66.78 |
| Q3 2014 | +15,800 | Add 28.13% | 71,966 | $58.92 |
| Q4 2014 | -45,572 | Reduce 63.32% | 26,394 | $74.15 |
| Q1 2015 | +3,226 | Add 12.22% | 29,620 | $77.25 |
| Q2 2015 | -1,097 | Reduce 3.70% | 28,523 | $64.12 |
| Q3 2015 | -1,250 | Reduce 4.38% | 27,273 | $74.25 |
| Q4 2015 | -1,239 | Reduce 4.54% | 26,034 | $72.90 |
| Q1 2016 | -225 | Reduce 0.86% | 25,809 | $78.31 |
| Q2 2016 | -9,965 | Reduce 38.61% | 15,844 | $92.84 |
| Q3 2016 | +49,069 | Add 309.70% | 64,913 | $112.74 |
| Q4 2016 | +86,427 | Add 133.14% | 151,340 | $117.27 |
| Q1 2017 | +59,255 | Add 39.15% | 210,595 | $154.61 |
| Q2 2017 | +20,317 | Add 9.65% | 230,912 | $161.42 |
| Q3 2017 | -97,389 | Reduce 42.18% | 133,523 | $155.49 |
| Q4 2017 | +44,695 | Add 33.47% | 178,218 | $156.38 |
| Q1 2018 | +52,641 | Add 29.54% | 230,859 | $191.39 |
| Q2 2018 | +14,699 | Add 6.37% | 245,558 | $217.94 |
| Q3 2018 | +3,442 | Add 1.40% | 249,000 | $249.66 |
| Q4 2018 | +20,337 | Add 8.17% | 269,337 | $186.02 |
| Q1 2019 | +6,324 | Add 2.35% | 275,661 | $223.60 |
| Q2 2019 | -130,386 | Reduce 47.30% | 145,275 | $275.33 |
| Q3 2019 | -41,964 | Reduce 28.89% | 103,311 | $271.93 |
| Q4 2019 | -3,960 | Reduce 3.83% | 99,351 | $261.13 |
| Q1 2020 | -32,118 | Reduce 32.33% | 67,233 | $242.25 |
| Q2 2020 | -19,913 | Reduce 29.62% | 47,320 | $325.25 |
| Q3 2020 | +6,697 | Add 14.15% | 54,017 | $386.08 |
| Q4 2020 | +6,738 | Add 12.47% | 60,755 | $495.00 |
| Q1 2021 | -5,388 | Reduce 8.87% | 55,367 | $489.30 |
| Q2 2021 | -1,586 | Reduce 2.86% | 53,781 | $631.54 |
| Q3 2021 | +38,261 | Add 71.14% | 92,042 | $621.90 |
| Q4 2021 | -21,678 | Reduce 23.55% | 70,364 | $658.46 |
| Q1 2022 | -24,358 | Reduce 34.62% | 46,006 | $547.06 |
| Q2 2022 | -18,109 | Reduce 39.36% | 27,897 | $347.56 |
| Q3 2022 | -7,449 | Reduce 26.70% | 20,448 | $325.80 |
| Q4 2022 | -2,333 | Reduce 11.41% | 18,115 | $403.83 |
| Q1 2023 | +1,347 | Add 7.44% | 19,462 | $497.50 |
| Q2 2023 | +6,726 | Add 34.56% | 26,188 | $502.23 |
| Q3 2023 | -13,107 | Reduce 50.05% | 13,081 | $437.27 |
| Q4 2023 | +1,364 | Add 10.43% | 14,445 | $555.05 |
| Q1 2024 | +42,924 | Add 297.15% | 57,369 | $539.93 |
| Q2 2024 | -27,834 | Reduce 48.52% | 29,535 | $487.20 |
| Q3 2024 | +22,994 | Add 77.85% | 52,529 | $505.22 |
| Q4 2024 | +70,150 | Add 133.55% | 122,679 | $413.44 |
| Q1 2025 | +53,106 | Add 43.29% | 175,785 | $414.11 |
| Q2 2025 | +47,534 | Add 27.04% | 223,319 | $531.50 |
| Q3 2025 | -88,165 | Reduce 39.48% | 135,154 | $631.89 |
Cliff Asness's IDEXX Laboratories Investment FAQs
Cliff Asness first purchased IDEXX Laboratories, Inc. (IDXX) in Q4 2012, acquiring 28,180 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held IDEXX Laboratories, Inc. (IDXX) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to IDEXX Laboratories, Inc. (IDXX) was in Q4 2016, adding 151,340 shares worth $17.75 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 135,154 shares of IDEXX Laboratories, Inc. (IDXX), valued at approximately $85.4 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, IDEXX Laboratories, Inc. (IDXX) represents approximately 0.05% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in IDEXX Laboratories, Inc. (IDXX) was 275,661 shares, as reported at the end of Q1 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.